Litigation Details for Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

Docket	1:09-cv-00703	Date Filed	2009-09-18
Court	District Court, D. Delaware	Date Terminated	2012-08-09
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,211,267; 7,232,572
Link to Docket	External link to docket

Details for Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-09-18				External link to document

Litigation summary and analysis for: Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

Last updated: June 15, 2026

Research Foundation of State University of New York v. Impax Laboratories Inc. 1:09-cv-00703 litigation summary: claims, posture, and settlement impact

What is the lawsuit Research Foundation of State University of New York v. Impax Laboratories Inc. (1:09-cv-00703) about?

Executive summary: The case Research Foundation of State University of New York v. Impax Laboratories Inc. (1:09-cv-00703) is a patent infringement dispute tied to an ANDA filing against an FDA-approved drug associated with technology licensed or assigned from the Research Foundation of State University of New York (SUNY Research Foundation). The litigation’s practical purpose was to block or delay Impax’s generic entry by challenging one or more asserted patents through the ANDA “patent carve-out” framework (commonly pursued via Orange Book listing and Hatch-Waxman notice mechanisms).

Actionable implication for generic risk: The case functioned as a typical Hatch-Waxman infringement injunction battle. The key commercial question is not the district-court merits alone but what patents remained enforceable after the litigation resolution and what launch date (and potentially licensing terms) followed.

---

Which patents did SUNY Research Foundation assert against Impax, and what was the asserted claim scope?

Executive summary: The case is an infringement action in which SUNY Research Foundation asserted one or more Orange Book-listed patents against Impax’s ANDA-based product. The claim scope aligned with the patents’ statutory categories, commonly including:

• Compositions/formulations (including active ingredient identity, specific compositions, polymorphs, salts, or dosage-form attributes),
• Methods of treatment or use (method-of-use claims tied to a therapeutic regimen), and/or
• Manufacturing or process claims.

Why claim scope matters: In generic cases, even a win on a narrow claim does not always preserve exclusivity if other listed patents expire later or remain valid. Conversely, settlements frequently resolve litigation by agreeing to delay launch until specific patent or exclusivity dates, not necessarily by extinguishing all claims.

---

What litigation posture did the court reach in 1:09-cv-00703 (motions, claim construction, and infringement/validity phases)?

Executive summary: In Hatch-Waxman cases like 1:09-cv-00703, the procedural arc typically includes:

1. Pleadings on infringement and invalidity, often with procedural defenses and related counterclaims.
2. Markman/claim construction resolving term meanings that determine whether the ANDA product infringes.
3. Summary judgment on discrete issues (indefiniteness, non-infringement, lack of written description, obviousness, or anticipation depending on the patent facts).
4. A decision or settlement that determines whether Impax can launch.

Business takeaway: The dispositive driver for investors and licensing teams is whether the court:

• reached final validity determinations, or
• resolved the case by settlement (which commonly ends litigation without a full appellate record on all issues).

---

When does exclusivity end, and how does the case affect Impax’s ability to launch before patent expiration?

Executive summary: The practical exclusivity question is whether the patents asserted in 1:09-cv-00703 controlled the earliest lawful generic entry date.

In Hatch-Waxman disputes, exclusivity typically survives until the relevant:

• Patent expiration date (or later if injunction relief applies), or
• Final resolution of the asserted patents, or
• Settlement agreement terms that can set a launch date independent of natural expiration.

Commercial impact framework:

• If the case settled with a paid delay construct (industry label), the settlement often includes a fixed no-launch date and sometimes additional terms like covenants not to sue.
• If the case resolved in the brand’s favor on validity and infringement, Impax’s generic launch is delayed until expiry or a successful appeal.

---

What Orange Book status issue did SUNY Research Foundation and Impax litigate?

Executive summary: Patent litigation in this posture typically revolves around Orange Book-listed patents and whether Impax’s ANDA:

• included a Paragraph IV certification (asserting non-infringement or invalidity), and
• provided a statutory basis for litigation under 35 U.S.C. § 271(e)(2).

Decision relevance: Orange Book listing status can determine:

• which patents are eligible for immediate ANDA-based infringement claims,
• whether certain patents drop out due to expiration or procedural defects, and
• which patents remain actionable at the time of settlement.

---

Was the litigation resolved by settlement, and what does that imply for follow-on generic challenges?

Executive summary: For cases in this category, resolution is frequently by settlement rather than a fully litigated merits decision. When settlement occurs, it typically produces:

• a dismissal of the infringement action,
• a launch commitment schedule, and
• a license or covenant structure that can bind the parties to certain conduct.

Follow-on risk lens: Even if the direct dispute settles, it can:

• narrow which patents remain enforceable against later ANDA filers,
• influence how other generics position around design-arounds,
• shape negotiation leverage for future patent waves tied to formulation variants or additional strengths.

---

Which FDA pathway and ANDA mechanism were implicated, and what is the generic launch risk for Impax?

Executive summary: The litigation’s procedural posture indicates an ANDA-based generic challenge where Impax pursued FDA approval of an equivalent product and used a certification pathway that enabled the brand’s patent infringement claim.

Launch risk indicators:

• If settlement restricts launch until a defined date, generic entry risk is largely contractual rather than purely patent-driven.
• If litigation ended on merits and the brand’s patents were upheld, generic entry risk increases sharply because future work must design around or wait out expiration.

---

How strong is the patent estate in 1:09-cv-00703 for business planning (validity durability, likely claim coverage, and design-around flexibility)?

Executive summary: The strength of the asserted estate depends on:

• whether patents are core composition/method claims or narrower dependent claims,
• whether courts found claims valid and infringed (or whether disputes were resolved earlier on procedural grounds),
• whether the asserted patents correspond to structural limitations (design-around possible) or treatment regimen limitations (harder to design around).

Planning rule for licensors: In many SUNY-linked technology portfolios, the earliest patents often include foundational scope, but continuation families and formulation-specific patents can create a second layer of exclusivity even if early patents fall. Without the complete asserted list and outcomes, the business inference is limited to the litigation’s function: it is a gatekeeping dispute intended to delay ANDA entry.

---

What patent litigation affects subsequent biosimilar-like risk in ANDA cases (analogous risk framing)?

Executive summary: ANDA disputes do not involve biosimilar exclusivity, but the risk pattern is similar in business terms:

• early-stage litigation can block initial market entry,
• later waves arise from other listed patents (continuations, formulation patents, secondary patents),
• settlement terms can affect follow-on generic filers through covenants.

Practical impact: For Impax, later market entries can be restricted if the settlement included broad covenants, or if later patents remain unadjudicated but still listed and enforceable.

---

Key takeaways on 1:09-cv-00703 for litigation, licensing, and investment decisions

• The case is a Hatch-Waxman-style patent infringement suit tied to an ANDA entry by Impax against a SUNY Research Foundation patent right.
• The litigation is oriented around Orange Book-listed patents and the statutory 271(e)(2) infringement mechanism.
• The business outcome is determined less by pleadings than by the final resolution mechanism, typically either court determinations on validity/infringement or settlement terms that set launch timing.
• Post-dispute market strategy for Impax and competitors depends on which patents:
  • remain enforceable,
  • are covered by any settlement covenants,
  • and expire or drop out on a defined timetable.

---

FAQs

1) What is the jurisdiction and case type for 1:09-cv-00703?

A federal patent infringement action brought in district court under the ANDA patent-litigation framework, assigning jurisdiction over infringement claims connected to FDA approval submissions.

2) What does the “1:09-cv-00703” caption tell about timing and posture?

It indicates the case was filed in 2009, consistent with an Orange Book- and Paragraph IV-driven dispute timeline around that period’s ANDA filings.

3) Do settlements in Hatch-Waxman cases typically include launch dates or only covenants?

Typically both: a settlement often includes a launch timing restriction and a covenant/dismissal structure governing conduct until the agreed trigger date.

4) How do Orange Book listing changes during litigation affect the case?

If patents expire or are removed, the statutory infringement claims can narrow to remaining asserted patents, changing the leverage and settlement dynamics.

5) Does winning infringement on a narrow claim always block generic entry fully?

Not always. Blocking depends on the remaining patent wall: other listed patents or additional wave patents can still delay entry, while a narrow claim win may not stop design-around or launch against unasserted patents.

---

References

No sources were provided in the prompt, and no citations can be produced without verifiable docket text (e.g., PACER docket entries, court opinion, or settlement documents).